一分钟看懂
这是一项关于小细胞肺癌的III 期研究，登记的药物或干预包括Pembrolizumab 200 mg；Pembrolizumab 400 mg；Pembrolizumab placebo (saline)；Olaparib 300 mg BID；Olaparib matching placebo；Etoposide 100 mg/m^2；，当前状态为研究进行中，已停止招募。登记地点显示中国北京、重庆、福州、厦门等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pembrolizumab 200 mg；Pembrolizumab 400 mg；Pembrolizumab placebo (saline)；Olaparib 300 mg BID；Olaparib matching placebo；Etoposide 100 mg/m^2；Platinum, investigator's choice；Standard Thoracic Radiotherapy；Prophylactic Cranial Irradiation (PCI) · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital ( Site 3102) · 北京
- Cancer Hospital Chinese Academy of Medical Sciences ( Site 3104) · 北京
- Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 3140) · 北京
- Beijing Cancer Hospital ( Site 3127) · 北京
- Chongqing Cancer Hospital ( Site 3135) · 重庆
- Daping Hospital,Third Military Medical University ( Site 3136) · 重庆
- Fujian Provincial Cancer Hospital ( Site 3126) · 福州
- The First Affiliated Hospital of Xiamen University ( Site 3121) · 厦门
- Peking University Shenzhen Hospital ( Site 3118) · 深圳
- Cancer Hospital Chinese Academy Of Medical Sciences. Shenzhen Center ( Site 3113) · 深圳
- Henan Cancer Hospital ( Site 3105) · 郑州
- Tongji Medical College Huazhong University of Science and Technology ( Site 3138) · 武汉
- Union Hospital, Tongji Medical College of HUST ( Site 3123) · 武汉
- Hubei Cancer Hospital ( Site 3120) · 武汉
- Xiangya Hospital of Central South University ( Site 3137) · 长沙
- Second Xiangya Hospital of Central-South University ( Site 3128) · 长沙
- Hunan Cancer Hospital ( Site 3133) · 长沙
- Jiangsu Cancer Hospital ( Site 3139) · 南京
- The Second Affiliated Hospital of Nanchang University ( Site 3106) · 南昌
- The First Hospital of Jilin University ( Site 3132) · 长春
- Affiliated Cancer Hospital of Shandong First Medical University ( Site 3100) · 济南
- Shanghai Chest Hospital ( Site 3107) · 上海
- Shanghai Pulmonary Hospital ( Site 3101) · 上海
- West China Hospital of Sichuan University ( Site 3114) · 成都
- Tianjin Medical University Cancer Institute & Hospital ( Site 3103) · 天津
- Hangzhou Cancer Hospital ( Site 3129) · 杭州
- The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 3131) · 杭州
- Zhejiang Cancer Hospital ( Site 3108) · 杭州
公开的入选条件
- 1. Has pathologically (histologically or cytologically) confirmed Small Cell Lung Cancer (SCLC).
- Note: Note: Participants with histology showing a mixed tumor with small cell and non-small cell elements are not eligible.
- 2. Has Limited-Stage SCLC (Stage I-III, by AJCC 8th Edition Cancer Staging), and can be safely treated with definitive radiation doses.
- 3. Has no evidence of metastatic disease by whole body positron emission tomography /computed tomography (PET/CT scan), CT or magnetic resonance imaging (MRI) scans
- 4. Has at least 1 lesion that meets the criteria for being measurable, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
- 5. Has not received prior treatment (chemotherapy or radiotherapy or surgery resection) of LS-SCLC.
- 6. Is not expected to require tumor resection during the course of the study.
- 7. Must submit a pre-treatment tumor tissue sample (formalin-fixed, paraffin embedded blocks are preferred to slides) including cytologic sample, if tissue sample unavailable.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04624204；登记信息更新于 2026-09-10。